Skip to main content

Published locations for FDA grants priority review of acalabrutinib for second-line treatment of MCL

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. FDA grants priority review of acalabrutinib for second-line treatment of MCL

User login

  • Reset your password
  • /content/fda-grants-priority-review-acalabrutinib-second-line-treatment-mcl
  • /hematologynews/article/143823/lymphoma-plasma-cell-disorders/fda-grants-priority-review
  • /oncologypractice/article/143823/lymphoma-plasma-cell-disorders/fda-grants-priority-review
  • /hematology-oncology/article/143823/lymphoma-plasma-cell-disorders/fda-grants-priority-review
  • /b-cell-lymphoma-icymi/article/143823/lymphoma-plasma-cell-disorders/fda-grants-priority-review